Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-05-15

FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Spravato (esketamine hydrochloride) submitted by Janssen Pharmaceuticals. The action updates the drug's labeling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

SUPPL AP for SPRAVATO (ESKETAMINE HYDROCHLORIDE)